140 related articles for article (PubMed ID: 37625088)
41. Patient-centered change in the day-to-day impact of postmenopausal vaginal symptoms: results from a multicenter randomized trial.
Gibson CJ; Huang AJ; Larson JC; Mitchell C; Diem S; LaCroix A; Newton KM; Reed SD; Guthrie KA
Am J Obstet Gynecol; 2020 Jul; 223(1):99.e1-99.e9. PubMed ID: 31954158
[TBL] [Abstract][Full Text] [Related]
42. Effects of oral versus transdermal menopausal hormone treatments on self-reported sleep domains and their association with vasomotor symptoms in recently menopausal women enrolled in the Kronos Early Estrogen Prevention Study (KEEPS).
Cintron D; Lahr BD; Bailey KR; Santoro N; Lloyd R; Manson JE; Neal-Perry G; Pal L; Taylor HS; Wharton W; Naftolin F; Harman SM; Miller VM
Menopause; 2018 Feb; 25(2):145-153. PubMed ID: 28832429
[TBL] [Abstract][Full Text] [Related]
43. Influence of raloxifene on the efficacy of an estradiol-releasing ring for treating vaginal atrophy in postmenopausal women.
Pinkerton JV; Shifren JL; La Valleur J; Rosen A; Roesinger M; Siddhanti S
Menopause; 2003; 10(1):45-52. PubMed ID: 12544676
[TBL] [Abstract][Full Text] [Related]
44. Efficacy of Transdermal Estradiol and Micronized Progesterone in the Prevention of Depressive Symptoms in the Menopause Transition: A Randomized Clinical Trial.
Gordon JL; Rubinow DR; Eisenlohr-Moul TA; Xia K; Schmidt PJ; Girdler SS
JAMA Psychiatry; 2018 Feb; 75(2):149-157. PubMed ID: 29322164
[TBL] [Abstract][Full Text] [Related]
45. Modulating Effects of Progesterone on Spontaneous Nocturnal and Ghrelin-Induced GH Secretion in Postmenopausal Women.
Roelfsema F; Yang RJ; Bowers CY; Veldhuis JD
J Clin Endocrinol Metab; 2019 Jun; 104(6):2385-2394. PubMed ID: 30721950
[TBL] [Abstract][Full Text] [Related]
46. Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause.
Labrie F; Archer DF; Koltun W; Vachon A; Young D; Frenette L; Portman D; Montesino M; Côté I; Parent J; Lavoie L; BSc AB; Martel C; Vaillancourt M; Balser J; Moyneur É;
Menopause; 2018 Nov; 25(11):1339-1353. PubMed ID: 30358731
[TBL] [Abstract][Full Text] [Related]
47. Treatment of menopausal symptoms with three low-dose continuous sequential 17β-estradiol/progesterone parenteral monthly formulations using novel non-polymeric microsphere technology.
Cortés-Bonilla M; Bernardo-Escudero R; Alonso-Campero R; Francisco-Doce MT; Hernández-Valencia M; Celis-González C; Márquez-Oñate R; Chedraui P; Uribe JA
Gynecol Endocrinol; 2015 Jul; 31(7):552-9. PubMed ID: 26062108
[TBL] [Abstract][Full Text] [Related]
48. Estradiol/progesterone-releasing vaginal rings for hormone replacement therapy in postmenopausal women.
Hamada AL; Maruo T; Samoto T; Yoshida S; Nash H; Spitz IM; Johansson E
Gynecol Endocrinol; 2003 Jun; 17(3):247-54. PubMed ID: 12857433
[TBL] [Abstract][Full Text] [Related]
49. Vaginal ring delivering estradiol and progesterone: a possible alternative to relieve climacteric symptoms.
Ben-Chetrit A; Hochner-Celnikier D; Lindenberg T; Zacut D; Shimonovitz S; Gelber H; Spitz IM
Isr Med Assoc J; 2005 May; 7(5):302-6. PubMed ID: 15909462
[TBL] [Abstract][Full Text] [Related]
50. Efficacy and safety of vaginal estriol and progesterone in postmenopausal women with atrophic vaginitis.
Chollet JA; Carter G; Meyn LA; Mermelstein F; Balk JL
Menopause; 2009; 16(5):978-83. PubMed ID: 19390463
[TBL] [Abstract][Full Text] [Related]
51. TX-004HR Improves Sexual Function as Measured by the Female Sexual Function Index in Postmenopausal Women With Vulvar and Vaginal Atrophy: The REJOICE Trial.
Kingsberg SA; Derogatis L; Simon JA; Constantine GD; Graham S; Bernick B; Gasper G; Mirkin S
J Sex Med; 2016 Dec; 13(12):1930-1937. PubMed ID: 27692842
[TBL] [Abstract][Full Text] [Related]
52. Technological evolution in the radiofrequency treatment of vaginal laxity and menopausal vulvo-vaginal atrophy and other genitourinary symptoms: first experiences with a novel dynamic quadripolar device.
Vicariotto F; Raichi M
Minerva Ginecol; 2016 Jun; 68(3):225-36. PubMed ID: 27206062
[TBL] [Abstract][Full Text] [Related]
53. Pharmacokinetics, safety and preliminary pharmacodynamic evaluation of DARE-VVA1: a soft gelatin capsule containing tamoxifen for the treatment of vulvovaginal atrophy.
Thurman A; Hull L; Stuckey B; Hatheway J; Mauck C; Zack N; Friend D
Climacteric; 2023 Oct; 26(5):479-488. PubMed ID: 37288962
[TBL] [Abstract][Full Text] [Related]
54. Estradiol softgel inserts for the treatment of VVA symptoms: an expert opinion.
Liu JH; Bernick B; Mirkin S
Expert Opin Drug Deliv; 2020 Nov; 17(11):1573-1581. PubMed ID: 32877254
[TBL] [Abstract][Full Text] [Related]
55. The effect of transdermal and vaginal estrogen therapy on markers of postmenopausal estrogen status.
Gupta P; Ozel B; Stanczyk FZ; Felix JC; Mishell DR
Menopause; 2008; 15(1):94-7. PubMed ID: 17882008
[TBL] [Abstract][Full Text] [Related]
56. Estradiol 1 mg and drospirenone 2 mg as hormone replacement therapy in postmenopausal Chinese women.
Lin SQ; Sun LZ; Lin JF; Yang X; Zhang LJ; Qiao J; Wang ZH; Xu YX; Xiong ZA; Zhou YZ; Wang ML; Zhu J; Chen SR; Su H; Yang CS; Wang SH; Zhang YZ; Dong XJ
Climacteric; 2011 Aug; 14(4):472-81. PubMed ID: 21469973
[TBL] [Abstract][Full Text] [Related]
57. Sublingual administration of micronized estradiol and progesterone, with and without micronized testosterone: effect on biochemical markers of bone metabolism and bone mineral density.
Miller BE; De Souza MJ; Slade K; Luciano AA
Menopause; 2000; 7(5):318-26. PubMed ID: 10993031
[TBL] [Abstract][Full Text] [Related]
58. Pharmacokinetics, pharmacodynamics, safety and tolerability of an intravaginal ring releasing anastrozole and levonorgestrel in healthy premenopausal women: a Phase 1 randomized controlled trial.
Schultze-Mosgau MH; Waellnitz K; Nave R; Klein S; Kraetzschmar J; Rautenberg T; Schmitz H; Rohde B
Hum Reprod; 2016 Aug; 31(8):1713-22. PubMed ID: 27390369
[TBL] [Abstract][Full Text] [Related]
59. Vascular Effects of Early versus Late Postmenopausal Treatment with Estradiol.
Hodis HN; Mack WJ; Henderson VW; Shoupe D; Budoff MJ; Hwang-Levine J; Li Y; Feng M; Dustin L; Kono N; Stanczyk FZ; Selzer RH; Azen SP;
N Engl J Med; 2016 Mar; 374(13):1221-31. PubMed ID: 27028912
[TBL] [Abstract][Full Text] [Related]
60. Estradiol vaginal inserts (4 µg and 10 µg) for treating moderate to severe vulvar and vaginal atrophy: a review of phase 3 safety, efficacy and pharmacokinetic data.
Constantine GD; Simon JA; Pickar JH; Archer DF; Bernick B; Graham S; Mirkin S
Curr Med Res Opin; 2018 Dec; 34(12):2131-2136. PubMed ID: 30238814
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
